Latanoprost punctual plug delivery system is effective in glaucoma treatment

Article

The latanoprost punctual plug delivery system (L-PPDS) is a safe and effective way of administering glaucoma medication, according to ocular company QLT.

The latanoprost punctual plug delivery system (L-PPDS) is a safe and effective way of administering glaucoma medication, according to ocular company QLT.

A phase II trial was conducted on 95 patients and involved the upper and lower puncta for delivery of a daily drug load. The aim was to compare clinical outcomes between latanoprost and daily Xalatan eye drops.

The primary endpoint was the mean change in IOP from baseline at 2 weeks. The secondary endpoints were the mean change in IOP from baseline at 4 weeks and the mean percentage change in IOP from baseline at 2 and 4 weeks.

After 2 weeks of treatment the mean change in IOP was statistically significant at a baseline of -6.2 mmHg. Of the patients studied, 73% presented with an IOP reduction compared to baseline of 5 mmHg or more and 51% demonstrated a reduction of 6 mmHg or more. At 2 weeks the mean change in IOP baseline was statistically significant at -24.3%.

IOP also changed significantly after 4 weeks of L-PPDS. The mean change from baseline was -5.7 mmHg. Out of the patients, 60% showed a reduction of IOP vs baseline of 5 mmHg or higher.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.